valdecoxib


Also found in: Dictionary, Thesaurus, Wikipedia.
Related to valdecoxib: rofecoxib, Parecoxib

Bextra

A next-generation NSAID Cox-2 inhibitor used for managing pain due to osteoarthritis, rheumatoid arthritis, dysmenorrhea, etc.
 
Adverse effects
Rarely, serious skin and hypersensitivity reactions (e.g., Stevens Johnson syndrome); toxic epidermal necrolysis; exfoliative dermatitis; erythema multiforme, possibly requiring hospitalisation; Bextra is contraindicated with sulfa drugs.

valdecoxib

See Bextra®.

valdecoxib

A COX-2 inhibitor drug used to treat OSTEOARTHRITIS, RHEUMATOID ARTHRITIS and DYSMENORRHOEA. A brand name is Bextra. In late 2004 the drug was shown to have cardiotoxic properties similar to those of rofecoxib and it was recommended that the drug should be withdrawn.
References in periodicals archive ?
Ott E, Nussmeier NA, Duke PC 2003 Efficacy and safety of the cyclo-oxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary bypass surgery Journal of Thoracic and Cardiovascular Surgery 125 1481-1492
Valdecoxib, a cyclooxygenase-2-specific inhibitor, is effective in treating primary dysmenorrhea.
However, in the years since the voluntary withdrawal of rofecoxib and valdecoxib from the market, few practitioners aside from rheumatologists prescribe selective COX-2 NSAIDs for children, according to survey results.
Based on increasing reports of thrombotic events associated with rofecoxib, celecoxib, and valdecoxib, the Food and Drug Administration (FDA) issued a health advisory on December 23, 2004, concerning the use of all COXIBs.
Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.
Efficacy and tolerability of valdecoxib in treating the signs and symptoms of severe rheumatoid arthritis: a 12-week multicenter randomized double-blind placebo-controlled study.
In addition, the off-label promotion of the arthritis drug valdecoxib (Bextra), the epilepsy drug gabapentin (Neurontin), and the schizophrenia drug olanzapine (Zyprexa) resulted in criminal prosecutions, fines and settlements of hundreds of millions of dollars, and a record-setting settlement of US$2.3 billion in the case of valdecoxib (see Gardiner Harris, "Pfizer Pays $2.3 Billion to Settle Marketing Case", The New York Times (2 September 2009), online: The New York Times <www.nytimes.com>).
(3) The findings of this meeting led to the withdrawal of valdecoxib from the market and labeling changes for prescription and nonprescription NSAIDs regarding increased risk of CV events and gastrointestinal (GI) bleeding.
Remote NSAID Exposure Indomethacin 1.71 Sulindac 1.41 Meloxicam 1.37 Rofecoxib 1.32 Piroxicam 1.18 Ibuprofen 1.11 Celecoxib 1.09 Naproxen 1.08 Valdecoxib 0.99 Nabumetone 0.83 Source: Dr.
* COX-2 specific inhibitors (cyclooxygenase inhibitors), are a fairly new class of NSAIDs that include celecoxib (Celebrex), valdecoxib (Bextra) and mobic (Meloxicam).